Company profile
Equillium company profile
Equillium Inc is a biotechnology company that develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with an unmet medical need. Its primary product candidate is EQ001, which is a clinical-stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis.
Business identity
- Website
- http://equilliumbio.com/
- Contact email
- [email protected]
- Phone number
- 858 412 5302
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $1M-$10M
- Founded
- 2017-01-01, Year
Headquarters
- Headquarters
- San Diego, California, United States
- Postal code
- 92037
- Country code
- US
- Continent
- North America